Vivax Working Group Workplan

Transcription

1 Vivax Working Group Workplan

2 Why Does The VxWG Exist? The choice before us is clear. If we continue with a business as usual approach employing the same level of resources and the same interventions we will face near-certain increases in malaria cases and deaths. World Malaria Report 2017 Dr Tedros Adhanom

3 Rise of Non Falciparum Malarias Thailand: Papua: Pf Pv Sattabongkot et al Trends in Parasite 2004;

4 A Dynamic Forum Public Private Partnerships Researchers Industry National Malaria Control Programs World Health Organisation Funders Networks

5 APMEN A network is only as good as : Its participants Its engagement Its relevance Prerequisites : Avoid duplication Flexible to changing priorities Dynamic / Responsive APMEN Vivax Working Group

6 Vivax Working Group Translational Research to Influence Policy and Practice Build Capacity Targeting Vivax Malaria in the Asia Pacific ,

7 1. Identify Knowledge Gaps Regular Reviews to identify critical bottlenecks and important novel innovations Literature Reviews Vivax surveyor published in Int J Para Drugs Drug Resist Mar Engagement with NMCPs/Researchers/Developers/WHO Discussion and interactions

8 2. Building Consensus Dialogue Round Table Discussions Genotyping workshop x2, Clinical trials workshop x2, G6PD workshop x2, Antimalarial resistance workshop Standardized protocols Surveys, trials and analyses Multicentred Pooling and Power Sharing data and experience Reaching across borders, increase power Requires trust

9 Evidence: The Challenge Diagnostics G6PD Subpatent parasitaemias Drug Discovery Geospatial Mapping Parasite Prevalence Drug Resistance G6PD Relapse Patterns Hots Spots Parasite Elimination All Stages All Species All Hosts Clinical Trials Safety, Efficacy and Effectiveness Pharmacokinetics Operational Research Case Detection RDTs / PCR Transmission Studies Access & Delivery Radical Cure Mass Drug Administration Health systems strengthening Parasite Genetics Host Genetics G6PD, CYP2d6

10 Surveillance Parasite Populations at risk of malaria Host - Populations at risk of haemolysis Quantitative and Qualitative Studies Deliverables: o o Geospatial mapping: CQR, G6Pd, CYP2d6 Online Genotyping and Serotyping Platforms VivaxGen - PLoS Negl Trop Dis Mar CQR

11 Diagnostics Parasite Ultrasensitive Host - G6PD RDTs and Biosensors Quantitative and Qualitative Studies Deliverables: o o o o G6PD Reference Centres Bangladesh and Indonesia Trial PoC diagnostics performance and acceptability Economic cost analyses Promote wider testing

12 Case Management Radical Cure: Blood Stage + Liver Stage Chloroquine Resistance ACT Alternatives Novel regimens / Drugs Tackling adherence Encouraging uptake Deliverables: Promote the safe and effective use of radical cure Paving the way for tafenoquine

13 4. Translation into Policy Priorities are determined by NMCPs NMCPs engaged / endorse in gathering relevant evidence New findings and innovations presented for feedback Additional data required to change policy StopMIP in 2017, IMPROV in 2018 Gain experience in a few selected target countries Wider promotion comes from the NMCP lobbying for change, not by researchers

14 5. Impact on the burden of disease Implementation Passive Policy Evidence Active

15 Deliverables Identify Evidence Gaps Build Consensus Generate Evidence Facilitate Collaboration and Build Capacity Leverage Funding Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Literature Reviews Workshops / Round Tables Standardised Surveys Test new diagnostics Qualitative Surveys Effectiveness Studies Geospatial Mapping Online Tools

16 Standardised Surveys Aims: Health care facility X sectional survey Micro/Submicro prevalence Prevalence of malaria, G6PD, Cyp2D6 Seroprevalence Evaluate novel diagnostics Parasite genotyping (CQR, HRP2 deletions) Community understanding + health seeking behaviour Evaluate perceptions and behaviour of health staff on PQ radical cure and G6PD testing APMEN funded Bangladesh, China, India, Indonesia, Laos, Nepal, Vietnam DFAT funded (TDRRCI) Indonesia x2, Malaysia Other?

17 Publications

18 Some Questions How can we maintain our relevance? Are we duplicating the role of other organisations? How can we reduce the number of meetings, but maintain our momentum? How can we work closer with the other working groups? Do we have the right partners for implementation and impact?

19 Annual Vivax Working Group Meeting October 2017 Bali, Indonesia

20 2017 Annual VxWG Meeting Annual Meeting October 9 th -11 th (Bali) Back to back with MMV stakeholder meeting 3 Day meeting with 110 delegates Participants from Ethiopia and Brazil STOPMiP Day maternal child health interventions Main theme - Improving Primaquine Adherence Lessons leant from TB Qualitative Surveys Professor Keon Peeters Antwerp Designing suitable interventions How to quantify effectiveness

21 Evaluation of Meeting Overall assessment of the APMEN VxWG Annual Meeting: 83% highly useful/relevant The meeting content, information and ideas: 79% highly useful/relevant The mix of presentation and discussion: 75% well balanced The ability of the VxWG to make decisions and action plan: 50%

22 Feedback Current VxWG Priorities still relevant But Days too long! Full day of maternal child health was too much More opportunity for sharing CPs experiences Split discussions into late control phase and end stage elimination We need an update session Recent Advances More discussion on better Advocacy

23 Improving Synergies Between Working Groups Integrating Surveillance of Parasite, Host and Vector Surveillance tied to Reaction Greater communication (combined meetings) Greater online tools in same location Data management workshops